Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA; Department of Infectious Diseases, Hartford Hospital, Hartford, CT, USA.
Clin Ther. 2019 Oct;41(10):2162-2170. doi: 10.1016/j.clinthera.2019.08.005. Epub 2019 Sep 7.
Eravacycline is a broad-spectrum, intravenous fluorocycline antibiotic approved for the treatment of complicated intra-abdominal infections in adults. A 60-minute infusion is recommended for each infused dose. Compatibility data that may allow convenient Y-site administration of eravacycline with other parenteral medications are unavailable. We aimed to determine the physical compatibility of eravacycline with other intravenous medications by simulated Y-site administration.
Eravacycline was reconstituted according to published prescribing information and diluted with 0.9% sodium chloride to a concentration of 0.6 mg/mL. Simulated Y-site administration was performed by mixing 5 mL of eravacycline with an equal volume of 51 other intravenous medications, including crystalloid and carbohydrate hydration fluids and 20 antimicrobials. Secondary medications were assessed at the upper range of concentrations considered standard for intravenous infusion. Mixtures underwent visual inspection and turbidity measurement immediately on mixture and at 3 subsequent time points (30, 60, and 120 minutes after admixture), and pH was measured at 60 minutes for comparison with the baseline value of the secondary medication.
Eravacycline was physically compatible with 41 parenteral drugs (80%) by simulated Y-site administration. Incompatibility was observed with albumin, amiodarone hydrochloride, ceftaroline fosamil, colistimethate sodium, furosemide, meropenem, meropenem/vaborbactam, micafungin sodium, propofol, and sodium bicarbonate.
Eravacycline for injection was physically compatible with most parenteral medications assessed. Pharmacists and nurses should be knowledgeable of the observed incompatibilities with eravacycline to prevent the unintentional mixing of incompatible intravenous medications.
依拉环素是一种广谱、静脉用氟环素抗生素,批准用于治疗成人复杂性腹腔内感染。建议每输注一次给予 60 分钟的输注。目前尚无数据表明依拉环素可与其他肠外药物在 Y 型部位方便地给药。我们旨在通过模拟 Y 型部位给药来确定依拉环素与其他静脉内药物的物理相容性。
依拉环素根据已发布的说明书进行配制,并使用 0.9%氯化钠稀释至 0.6mg/mL 的浓度。通过将 5mL 依拉环素与 51 种其他静脉内药物(包括晶体液和碳水化合物水化液以及 20 种抗菌药物)等体积混合来进行模拟 Y 型部位给药。将次级药物的浓度调整至静脉输注标准浓度的上限范围进行评估。混合液在混合后即刻以及混合后 30、60 和 120 分钟时进行目视检查和浊度测量,并在 60 分钟时测量 pH 值,与次级药物的基线值进行比较。
依拉环素通过模拟 Y 型部位给药与 41 种(80%)肠外药物在物理上相容。与白蛋白、盐酸胺碘酮、头孢洛林酯、黏菌素甲磺酸钠、呋塞米、美罗培南、美罗培南/沃博巴坦、米卡芬净钠、丙泊酚和碳酸氢钠观察到不相容。
注射用依拉环素与评估的大多数肠外药物在物理上相容。药剂师和护士应了解与依拉环素观察到的不相容性,以防止意外混合不相容的静脉内药物。